Clinical Rheumatology

, Volume 38, Issue 2, pp 609–610 | Cite as

Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease

  • Silvia TamaniniEmail author
  • Micaela Fredi
  • Francesca Crisafulli
  • Maria Grazia Lazzaroni
  • Angela Tincani
  • Franco Franceschini
Letter to the Editor

Vedolizumab (VDZ) is a gut-selective antibody to α4β7 integrin for the treatment of inflammatory bowel disease (IBD). The role of VDZ in rheumatological manifestations is still not clear and conflicting data are reported in literature. New onset or exacerbation of arthritis and sacroiliitis in patients treated with VDZ has recently been reported in small case series [1, 2]. Furthermore, inflammatory arthralgia/arthritis was observed in 34 out of 247 patients (13.8%) receiving VDZ [3], yet the increased risk of developing arthralgia was reported as not significant in another study [4]. A selective increased risk of developing arthropathy has been reported in Crohn’s disease (CD) but not in ulcerative colitis (UC) comparing anti-TNF with VDZ treated patients [5]. By contrast, other studies involving small cohorts [6] not only did not report new induction or flare of arthritis and/or sacroiliitis but noted improvement in patients with active spondyloarthritis (SpA) after VDZ. In...


Compliance with ethical standards




  1. 1.
    Wendling D, Sondag M, Verhoeven F, Vuitton L, Koch S, Prati C (2018) Arthritis occurrence or reactivation under vedolizumab treatment for inflammatory bowel disease: a four cases report. Joint Bone Spine 85(2):255–256. CrossRefGoogle Scholar
  2. 2.
    Varkas G, Thevissen K, De Brabanter G, Van Praet L, Czul-gurdian F, Cypers H, De Kock J, Carron P, De Vos M, Hindryckx P, Arts J, Vanneuville I, Schoenaers P, Claerhout B, Abreu M, Van den Bosch F, Elewaut D (2017) An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis 76:878–881. CrossRefGoogle Scholar
  3. 3.
    Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier A-L, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A (2018) Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther 47:485–493. CrossRefGoogle Scholar
  4. 4.
    Cai T, Lin T-C, Bond A, Huang J, Kane-Wanger G, Cagan A, Murphy SN, Ananthakrishnan AN, Liao KP (2018) The association between arthralgia and vedolizumab using natural language processing. Inflamm Bowel Dis 24(10):2242–2246. CrossRefGoogle Scholar
  5. 5.
    Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Brandee Pappalardo B, Ganguli A, Wang A (2018) Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 24:1876–1882. CrossRefGoogle Scholar
  6. 6.
    Orlando A, Orlando R, Ciccia F, Renna S, Rizzo a CM, Macaluso FS (2017) Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis 76:e31. CrossRefGoogle Scholar
  7. 7.
    Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG (2017) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66:839–851. CrossRefGoogle Scholar
  8. 8.
    Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M (2018) Effectiveness and safety of vedolizumab in anti-TNF-naive patients with inflammatory bowel diseases – a multicenter retrospective european study. Inflamm Bowel Dis 24(11):2442–2451. CrossRefGoogle Scholar
  9. 9.
    Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D, Cappello M, Morreale GC, Siringo S, Privitera AC, Ferracane C, Belluardo N, Alberghina N, Ventimiglia M, Rizzuto G, Renna S, Cottone M, Orlando A (2018) The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis 50:675–681. CrossRefGoogle Scholar
  10. 10.
    Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Weber U, Wei J, Sieper J (2011) The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31. CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1. Rheumatology and Clinical Immunology Unit, ASST-Spedali Civili of BresciaBresciaItaly
  2. 2. Rheumatology and Clinical Immunology Unit, University of BresciaBresciaItaly

Personalised recommendations